Interleukin 2 (IL-2), a Th1 lymphocytederived cytokine, is thought to play an important role in the pathogenesis of type 2 diabetes and rheumatoid arthritis (RA). The aim of our study was to evaluate changes in serum IL-2 levels and their correlation with glucose metabolism abnormalities, such as insulin resistance, in patients with RA. Thirty-six subjects with varying degrees of disease activity and 20 healthy age-, sex-and body mass indexmatched control individuals were evaluated. Patients with any causes of peripheral insulin resistance were excluded. After a 12-h overnight fast, fasting insulin levels, homeostatic model assessment-insulin resistance (HOMA-IR) estimated insulin sensitivity, and serum IL-2 levels were significantly higher in all patients with RA than in the control individuals. Fasting insulin, HOMA-IR scores and IL-2 levels were correlated in the RA group. This study showed that patients with RA have altered IL-2 regulation, and that there was a significant correlation between serum IL-2 levels and insulin sensitivity.
Introduction
Insulin resistance is defined clinically as the inability of a known quantity of exogenous or endogenous insulin to increase glucose uptake and utilization in an individual to the same extent as in the normal population. 1 It is now well established that insulin resistance is a strong predictor of type 2 diabetes. 2, 3 Interleukin (IL) 2, a Th1 lymphocyte-derived cytokine, is the principal autocrine growth factor that promotes T-cell activation and proliferation. 4 Currently, IL-2 is considered to play an important role in the pathogenesis of type 1 diabetes. 5 The production of cytokines by activated T cells in synovial tissue plays an important role in the pathophysiology of rheumatoid arthritis (RA). 6 Type II collagen-reactive T lymphocytes selectively accumulate in the inflamed joint of patients with RA, and they may play an important role in the pathogenesis of RA. 7 Therapeutic agents for the treatment of RA that will target components of the immune activation and co-stimulatory pathways are currently in development. These include antibodies against the IL-2 receptor and blockers of the CD28 and CD40 co-stimulatory pathways. Continuing research into the pathogenesis of RA will undoubtedly identify even more effective therapeutic approaches for the management of this disease in the future. 8 The aim of our study was to evaluate changes in serum IL-2 levels and their correlation with glucose metabolism abnormalities, such as insulin resistance, in patients with RA. All subjects gave informed consent to participate in the study. No one was taking any medication that altered insulin action. None reported any alteration of disease activity for at least 3 months before the study. All patients underwent routine investigations for accompanying metabolic, hepatic and renal diseases. No patient had any features of recent acute illness or clinical evidence of cardiovascular, kidney, liver or endocrine diseases. Patients with type 2 diabetes and other concomitant renal, hepatic or cardiac disease were excluded from the study.
Patients and methods
The diagnosis of RA was based on the American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis. 9 Fasting blood samples from all participants were collected via an intravenous catheter in ethylenediaminetetraacetate-coated (EDTA) venepuncture tubes, promptly centrifuged, separated and stored at -70°C until IL and insulin assays were performed. All subjects underwent a diagnostic protocol that included measurement of fasting IL-2 levels by enzyme-linked immunosorbent assay (Enzyme Immunoassay kit, Immunotech, Marseille, France). The inter-and intra-assay coefficients of variation were 2.4% and 3.0%, respectively. Glucose was measured using a glucose oxidase method (Hitachi 736 Auto Analyzer, Hitachi Co., Tokyo, Japan). Immunoreactive insulin was determined by double-antibody radioimmunoassay (Coat-aCount, Diagnostics Products Corp., LA, USA). Homeostatic model assessment-insulin resistance (HOMA-IR) estimated insulin sensitivity was calculated using the formula defined by Matthews et al: 10 Fasting insulin (µIU/ml) × HOMA-IR = fasting glucose (mmol/l) 22.5
With this method, a high HOMA-IR score is indicative of low insulin sensitivity.
STATISTICAL ANALYSIS
All data were presented as means ± SDs. For comparison of study and control data, the Mann-Whitney U-test was used. Pearson correlation analysis was used to estimate the relation between test parameters. P-values < 0.05 were considered significant.
Results
Fasting insulin levels were significantly higher in all patients with RA than in controls (P < 0.001; Table 1 ). HOMA-IR scores and serum IL-2 levels were also significantly higher in patients with RA than in controls (P < 0.001 and P < 0.001, respectively; Table 1 ). Fasting insulin, HOMA-IR and IL-2 were correlated in the whole group. There was a positive significant correlation between serum IL-2 level and fasting insulin level, and between serum IL-2 level and HOMA-IR score in patients with RA (r = 0.31, P < 0.05 and r = 0.30, P < 0.05, respectively).
Discussion
Rheumatoid arthritis is an inflammatory polyarthritis genetically linked to human leukocyte antigen (HLA)-DR4 and related haplotypes. RA synovial tissue is characterized by T-cell infiltration and activation of macrophage-like cells, strongly implicating a Tcell-antigen-presenting cell interaction in RA pathogenesis. 11 Brok et al. 12 investigated the prophylactic and therapeutic effects of a humanized monoclonal antibody, daclizumab, against the α-chain of the IL-2 receptor, CD25, and concluded that daclizumab has clinical potential for the treatment of RA during periods of active inflammation and for suppression of joint tissue destruction. Insulin signalling in target tissues results in a large array of biological outcomes. These events are essential for normal growth and development, and for normal homeostasis of glucose, fat and protein metabolism. 13 Insulin resistance is a common pathological state, in which target cells fail to respond to ordinary levels of circulating insulin. It is frequently associated with a number of diseases, including chronic infection, obesity and type 2 diabetes. 14 Penttinen 15 postulated that low-density lipoproteins, infections and smoking are also closely associated with insulin resistance, and that each of these factors may cause insulin resistance by the same mechanism. The first step in the cascade of events leading to insulin resistance is increased production of IL-2. This is followed by secretion of other cytokines, activation of macrophages and increased production of nitric oxide from L-arginine. The reduced amount of plasma L-arginine leads to decreased secretion of growth hormone and insulin-like growth (ILG) factor-1, leading to insulin resistance. High plasma IL-2 also causes decreased bioavailability of ILG factor-1 by reducing the production of androgenic hormones. 15 The vast and growing array of cytokines is the subject of intense research for those with potential to ameliorate diseases ranging from autoimmune disorders to cancer and O Öncül, C Top, S Özkan et al. O Öncül, C Top, S Özkan et al. IL-2 levels and insulin sensitivity in rheumatoid arthritis patients beyond. 16 Diabetes is thought to be an autoimmune disease caused by destruction of β-cells in pancreatic islets. IL-2 can enhance immune function by stimulating formation of cytolytic T cells. 17 Cytokines function at the cellular, microenvironmental level, but human cytokine assessment is most commonly performed at a macro level by measurement of serum cytokines. Jason et al. 18 investigated the relationships between serum and cellular cytokines, and reported that serum cytokines (IL-2, IL-4, IL-6, IL-8, IL-10, interferon-γ and tumour necrosis factor-α) may reflect peripheral blood cell cytokine production and balances. In this study, we also measured serum IL-2 levels to determine peripheral blood T-lymphocyte IL-2 production.
IL-2 levels and insulin sensitivity in rheumatoid arthritis patients
The present study clearly demonstrated that fasting insulin levels and HOMA-IR scores were significantly higher in all patients with RA than in controls. As far as we can ascertain from an extensive search of the literature, this study is the first to evaluate the importance of serum IL-2 levels in the development of insulin resistance in patients with RA. The study data showed a positive correlation between fasting insulin levels, HOMA-IR scores and serum IL-2 levels in patients with RA. Such a relationship may prove the pathogenic role of IL-2 in insulin resistance. Insulin resistance therefore seems to be the main metabolic abnormality that alters glucose metabolism, and decreases the sensitivity of peripheral tissues to insulin in patients with RA.
